Fac­ing a crit­i­cal Au­gust dead­line, House pass­es bill to reau­tho­rize FDA user fee pro­grams

In a mo­ment of bi­par­ti­san­ship, the US House of Rep­re­sen­ta­tives on Wednes­day passed a bill via voice vote to reau­tho­rize the pre­scrip­tion drug, gener­ic drug, med­ical de­vice and biosim­i­lar user fee pro­grams through 2022.

Sev­er­al rep­re­sen­ta­tives dis­cussed the is­sue of ex­pen­sive med­i­cines on the House floor Wednes­day, though none of the user fee pro­grams ad­dress the is­sue di­rect­ly. How­ev­er, speed­ing the re­view of gener­ic drugs could low­er some high-priced brand name drugs and gener­ic drugs with no com­pe­ti­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.